Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor

Kinouchi, Katsushi; Morita, Kiyozo; Nagahori, Ryuichi; Shinohara, Gen; Abe, Takayuki; Hara, Kazuhiro

doi:10.1007/s11748-011-0810-4

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct comparisons between different cardioplegic solutions revealed that the modified Calafiore cardioplegia had a superior contractility after CBP surgery when compared to HTK [ 49 ]. For adult pig models, additives such as ebselene [ 50 ], olprinone [ 51 ], diazoxide [ 52 ], and sivelestat [ 53 ] have been investigated. A reduction in myocardial IRI with the antioxidants ebselene and olprinone has been proven [ 50 , 51 ].…”

Section: Investigations In Pediatric Modelsmentioning

confidence: 99%

“…For adult pig models, additives such as ebselene [ 50 ], olprinone [ 51 ], diazoxide [ 52 ], and sivelestat [ 53 ] have been investigated. A reduction in myocardial IRI with the antioxidants ebselene and olprinone has been proven [ 50 , 51 ]. Diazoxide protected the integrity of the mitochondrial structure when applied to a cardioplegic solution [ 52 ].…”

Section: Investigations In Pediatric Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Relevance and Recommendations for the Application of Cardioplegic Solutions in Cardiopulmonary Bypass Surgery in Pigs

et al. 2021

View full text Add to dashboard Cite

Cardioplegic solutions play a major role in cardiac surgery due to the fact that they create a silent operating field and protect the myocardium against ischemia and reperfusion injury. For studies on cardioplegic solutions, it is important to compare their effects and to have a valid platform for preclinical testing of new cardioplegic solutions and their additives. Due to the strong anatomical and physiological cardiovascular similarities between pigs and humans, porcine models are suitable for investigating the effects of cardioplegic solutions. This review provides an overview of the results of the application of cardioplegic solutions in adult or pediatric pig models over the past 25 years. The advantages, disadvantages, limitations, and refinement strategies of these models are discussed.

show abstract

Section: Investigations In Pediatric Modelsmentioning

confidence: 99%

Section: Investigations In Pediatric Modelsmentioning

confidence: 99%

Relevance and Recommendations for the Application of Cardioplegic Solutions in Cardiopulmonary Bypass Surgery in Pigs

et al. 2021

View full text Add to dashboard Cite

show abstract

“…49,50 Studies in young pigs undergoing cardiopulmonary bypass have shown that inclusion of a phosphodiesterase III inhibitor (olprinone) in crystalloid cardioplegia improves recovery of left-ventricular function, reduces release of troponin-T and attenuates the development of arrhythmias. 49 Still, these drugs are positive inotropic agents that increase intracellular Ca 2+ levels 51 so they might be expected to actually exacerbate injury in cardioplegia. More studies of the underlying mechanisms are clearly needed.…”

Section: Other Pharmacological Strategiesmentioning

confidence: 99%

“…Other studies have used cardioplegia supplemented with a phosphodiesterase III inhibitor, based on reports that these agents can attenuate ischaemia and reperfusion injury possibly by reducing oxidative stress and cAMP‐, PKA‐, and p38 MAPK–dependent pathways . Studies in young pigs undergoing cardiopulmonary bypass have shown that inclusion of a phosphodiesterase III inhibitor (olprinone) in crystalloid cardioplegia improves recovery of left‐ventricular function, reduces release of troponin‐T and attenuates the development of arrhythmias . Still, these drugs are positive inotropic agents that increase intracellular Ca 2+ levels so they might be expected to actually exacerbate injury in cardioplegia.…”

Section: Pharmacologic Agents In Cardioplegia In Pre‐clinical Models mentioning

confidence: 99%

Novel cardioprotection strategies for the aged heart: evidence from pre‐clinical studies

Kane

Howlett

2016

Clin Exp Pharma Physio

View full text Add to dashboard Cite

The incidence of cardiovascular disease is rising as the population ages. This has led to an increase in the need to perform cardiac surgery in older patients. However, aged hearts are particularly susceptible to reperfusion injury following periods of myocardial ischaemia that occur during cardiac surgery. Indeed, older adults experience myocardial dysfunction and reduced survival post-surgery compared to younger people and certain groups, including older women and frail older adults, are at particular risk. This highlights the need to design cardioprotective strategies specifically for the ageing heart. Cardioprotection during surgery is often accomplished by perfusing the heart with chemical arresting agents, known as cardioplegic solutions. New protective strategies have been developed and tested in animal models, where cardioplegic solutions have been modified by changing their temperature, chemical components and/or the frequency of delivery. In addition, drugs designed to activate cardioprotective mechanisms or to inhibit mechanisms involved in injury have been added to improve the efficacy of these solutions. However, most experimental studies have developed and optimized cardioplegic solutions in hearts from younger male animals. This review discusses pre-clinical models used to optimize cardioplegic solutions, with an emphasis on the few studies that have used hearts from older animals. Pharmacologic agents that have been shown to enhance the benefits of cardioplegia in younger hearts and could, in theory, protect vulnerable older hearts are also considered. We emphasize the need to conduct studies in frail older animals of both sexes to facilitate translation of laboratory-based observations to the clinic.

show abstract

Superior restoration of left ventricular performance after prolonged single-dose del Nido cardioplegia in conjunction with terminal warm blood cardioplegic reperfusion

Nakao

Morita

Shinohara

et al. 2022

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor

Abstract: We concluded that TWBCP with olprinone reduces myocardial reperfusion injury by reducing oxidant-mediated lipid peroxidation, and it accelerates prompt and persistent LV functional recovery with suppression of reperfusion arrhythmia.

Cited by 4 publications

References 24 publications

Relevance and Recommendations for the Application of Cardioplegic Solutions in Cardiopulmonary Bypass Surgery in Pigs

Relevance and Recommendations for the Application of Cardioplegic Solutions in Cardiopulmonary Bypass Surgery in Pigs

Novel cardioprotection strategies for the aged heart: evidence from pre‐clinical studies

Superior restoration of left ventricular performance after prolonged single-dose del Nido cardioplegia in conjunction with terminal warm blood cardioplegic reperfusion

Contact Info

Product

Resources

About